Objective To evaluate whether a policy to treat latent tuberculosis identified by annual tuberculin sensitivity testing is effective for tuberculosis control in human immunodeficiency virus-infected patients in Hong Kong.
Tuberculin sensitivity testing and treatment of latent tuberculosis remains effective for tuberculosis control in human immunodeficiency virus-infected patients in Hong Kong
Introduction Tuberculosis (TB) is a major cause of illness and death in persons infected with human immunodeficiency virus (HIV). The geographical intersection of TB and the HIV epidemic has been devastating. 1 An estimated 1.4 million incident cases of HIVassociated TB occurred in 2008 worldwide, which accounted for 25% (0.5 million) of all global deaths from HIV infection. 2 In resource-constrained settings with a high burden of TB, treatment of latent TB infection in HIV-infected patients is highly effective in preventing TB. 3 However, the use of antiretroviral therapy (ART) per se also reduces the incidence of TB. 4, 5 It is therefore unclear whether treatment of latent TB infection as identified by annual tuberculin sensitivity testing (TST) will continue to be effective in a setting with universal access to ART and an intermediate burden of TB.
The burden of TB is intermediate in Hong Kong, where the overall prevalence of HIV is relatively low. 6 With effective implementation of prevention and control measures (particularly case-finding and treatment), the incidence of TB has decreased significantly over the past five decades. 7 In Hong Kong, the first HIV case was reported in 1984. As of the first quarter of 2012, the cumulative number of reported individuals with HIV infections was 5392. 8 In Hong Kong, combination ART has been readily available since 1997, and is currently being prescribed in line with treatment guidelines for developed countries. 9 The burden of TB in HIV-infected patients, however, remains a challenge in the territory. Over the past two decades, TB has remained the most important acquired immunodeficiency syndrome-defining condition in the local HIV-infected population. 6, 10 Moreover, TB endemicity in this locality renders HIV-infected patients prone to the infection early in the course of their HIV disease. To look into the effectiveness of a policy of annual TST and treatment of latent TB in HIV-infected patients in Hong Kong, we analysed data from a cohort of patients in a local HIV centre.
Methods

Study design, subjects, and definitions
The study population was drawn from the largest HIV clinic in Hong Kong, namely the Integrated Treatment Centre (ITC), Department of Health. The ITC provides specialist HIV care to patients, including ART, regular monitoring of CD4 counts, and HIV-1 RNA viral load determination every 3 to 6 months, drug adherence counselling, and psychosocial support. All patients underwent baseline chest radiography at the first clinic visit. In the ITC, TST was first introduced in July 1989. Subsequently, TST with 2 units of purified protein derivative RT23 were used at baseline and In the study period (1 July 1989 to 30 June 2011), all patients under care in the ITC who were started on ART during the study period and eligible for TST were included. Tuberculosis was defined as the first recorded TB diagnosis made by physicians in the TB and chest clinics or in any other hospitals during the study period. Eligible patients were followed up until the development of new TB or at the end of the study period on 30 June 2011. Patients were censored at the study end-point, or when they were lost to follow-up, their care transferred to another HIV clinic, had left Hong Kong, or died. The time-to-event was counted from the date of the last negative TST result to the date of TB diagnosis. In patients who did not receive TST, the time-to-event was counted from the date of initiation of ART to the date of TB diagnosis. The TB incidence rate was defined as the number of TB cases occurring per 100 patient-years of observation. Data collected included demographic features, body mass index (BMI), route of HIV transmission, clinical and immunological markers including CD4 count and HIV-1 viral load, haemoglobin level, and history of diabetes mellitus. In addition, clinical details pertaining to their subsequent TB infection and ART regimen were retrieved from the clinical information system of the ITC. Patients with a history of TB at HIV diagnosis and those who developed TB before ART were excluded.
Statistical analysis
Logistic regression was used for univariate analysis, 
Incidence of tuberculosis and factors associated with development of the disease
There were 33 cases of incident TB in the cohort, making the overall incidence rate of 0.59 case per 100 patient-years, among which 21 (64%) were pulmonary and 12 (36%) were extrapulmonary. The incidence rate of TB was lower in the 22 patients who received annual TST (0.41 per 100 patient-years), as compared with that in the 11 who did not (3.85 per 100 patientyears) [P<0.0001]. Univariate analysis showed that factors associated with development of incident TB included route of HIV transmission, baseline CD4 count, baseline haemoglobin level, and a history of TST (Table 2 ). Multivariate analysis showed that only a low baseline CD4 count and a history of TST were significant factors for incident TB. For those with a baseline CD4 count of ≥100 cells/mm 3 , the hazard ratio was 0.36 (95% CI, 0.16-0.85; P=0.02), and for those who received annual TST it was 0.26 (95% CI, 0.08-0.77; P=0.016) [ Table 2 ]. 
Tuberculosis incidence rates stratified by baseline CD4 count and timing after initiation of antiretroviral therapy
Among patients with baseline CD4 counts of <100 cells/mm 3 , the respective incidence rate of TB was 0.67 and 8.2 per 100 patient-years in those who received and did not receive annual TST. For patients with baseline CD4 count of ≥100 cells/mm 3 , the incidence rate of TB was 0.29 and 2.74 per 100 patient-years in those who received and did not receive annual TST, respectively.
The incidence of TB was highest within 90 days of initiating ART, especially for those with a low baseline CD4 count. For patients with a baseline CD4 count of ≤50 cells/mm 3 , the incidence rate of TB within 90 days of initiation of ART was 369 and 600 per 100 patient-years in those who received and did not receive annual TST, respectively. For patients with a baseline CD4 count of 51 to 100 cells/mm 3 , none who had received annual TST developed TB within 90 days of initiation of ART, while in those who did not the incidence rate was 480 per 100 patient-years. After 180 days of ART, the incidence rate of TB in patients who underwent annual TST was below 0.5 per 100 patient-years, regardless of the baseline CD4 count. Whereas in patients who did not undergo annual TST, the TB incidence rate ranged from 2 to 3 per 100 patient-years if the baseline CD4 count was >50 cells/mm 3 ( Table 3 ). The cumulative hazard of new TB over time after initiation of ART in patients with various baseline CD4 counts and a history of annual TST is shown in the Figure. 
Discussion
This is the first study addressing the policy of annual TST and treatment of latent TB infection in a setting of universal access to ART and an intermediate burden of TB. It showed that this policy appears to reduce the development of TB in the HIV-infected population in a setting such as Hong Kong.
In this study, the incidence of TB in HIV- CD4 counts (cells/mm 3 ) <100 With TST performed ≥100 With TST performed <100 Without TST performed ≥100 Without TST performed infected patients on ART was significantly lower in those who underwent annual TST than in those who did not, despite having similar baseline CD4 counts and other risk factors for TB. Moreover, recourse to annual TST was an independent factor associated with a reduced incidence of TB; the risk being reduced by 74%. Indeed, the overall incidence rate of TB in our cohort was 0.59 case per 100 patient-years, which is much lower than 0.8 to 2.83 per 100 patient-years reported in other Asian studies and in high-income settings in the ART era. [11] [12] [13] [14] [15] This lower incidence was likely to be attributable to the high coverage of annual TST (89%) and IPT (88%) for those who tested positive in our centre.
Similar to the findings in other studies, 16, 17 we observed that the highest incidence of TB occurred in patients with advanced HIV disease during the early period of ART initiation. The incidence of TB in our patients with baseline CD4 count of <100 cells/mm 3 was nevertheless lower in those who received annual TST as compared with those who did not, in which the finding was also applicable within first 90 days of ART initiation. Therefore, the early use of TST, especially at baseline (before or at the initiation of ART), is warranted to identify latent TB infection in these high-risk patients. The incidence of TB occurring more than 180 days after initiation of ART was also lower in our patients who received TST as compared with those who did not. This probably reflects that the treatment of latent TB infection as identified by annual TST continues to be effective late after initiation of ART, even when the risk of TB is considered to be much lower. 18 Overall, the majority of TB developed within 90 days of initiating ART. Therefore, baseline TST appears to be very important for the identification of latent TB infection followed by treatment. However, the additional value of such late repeat annual TST for all patients warrants further evaluation from the perspective of incremental benefits and costs.
Among our patients who have received TST and who had very low baseline CD4 count (≤50 cells/mm 3 ), incidence rate of TB was still high early after ART initiation, which might reflect a limitation of TST in these patients. While a recent study found that universal IPT did not reduce the incidence of TB in a population with a high TB burden, 19 our findings suggest that universal IPT at ART initiation could be studied selectively in HIV-infected patients with very low baseline CD4 count.
In this study, TST was used as the gold standard for the diagnosis of latent TB infection, even though Bacillus Calmette-Guérin (BCG) vaccination is incorporated into the childhood vaccination programme in Hong Kong. However, in one study it was shown that notwithstanding prior BCG vaccination, a significant influence on TST results was not evident in HIV-infected patients. 20 On the other hand, in HIV-infected patients the utility of interferon-gamma release assays (IGRAs) for the diagnosis of latent TB remains controversial, especially in settings with a high TB burden and for patients with low CD4 counts. [21] [22] [23] Moreover, a recent meta-analysis did not show consistently improved sensitivity of IGRAs compared with TST for the identification of HIV-infected patients who could benefit from IPT for latent TB. 24 However, in our setting with intermediate burden of TB and HIV infection, the use of IGRAs in those who did not receive TST in our cohort warrants further study. Similarly, it warrants further study in combination with TST as a means of achieving higher sensitivity and specificity for the diagnosis of latent TB infection.
We included only patients on ART in the analysis. In our centre, as of December 2011, the proportion of patients receiving combination ART was up to 85%. The use of ART is well-known to reduce the risk of TB in HIV infection. 25 Indeed, multivariate analysis showed that among all our patients eligible for annual TST, patients who were not on ART were strongly associated with incident TB (hazard ratio=7.74; 95% CI, 4.5-13.29; data not shown). Therefore, in our setting we believe that only including patients on ART reflects the genuine effectiveness of using annual TST and treatment of latent TB infection. Our study did not examine the incidence of TB in patients who were not on ART and who did not receive annual TST. However, given the high coverage of both ART and annual TST in our clinic, the proportion of such patients was small.
One limitation of our study was that though physicians who made the diagnosis of TB were blinded to HIV viral load and CD4 counts, there might have been variation in the diagnostic criteria of TB in different clinics and hospitals, especially in the small proportion of patients lacking microbiological proof. Second, in calculating the risk of incident TB, we included several known risk factors other than HIV disease status, including age, BMI, history of diabetes mellitus, and haemoglobin level. Yet data on several others (social class, ethnicity, nutritional status) were not collected, and thus not used to adjust for potential confounding. Moreover, the possibility of different exposures to TB among patients originating from places with different TB prevalences was not examined. Third, patients recruited in the later part of the study might not have been observed long enough for the development of TB. Fourth, 4% of the study population were lost to follow-up, which could have biased our analysis.
Conclusion
This study has shown the effective use of the policy of annual TST and treatment of latent TB in a setting with high coverage of ART and an intermediate TB
